Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory, is working to accelerate the pace of early-stage drug discovery by revolutionizing in vitro research on cell models. As an expansion on its SemaCyte Microcarrier Platform, semarion recently introduced the SemACytes Multiplexing Platform, which enables in situ multiplexing of adherent cells. This process is often slow and labor-intensive, with the industry spending roughly $10 billion annually on adhere